Diagnosing lung diseases with AI technology
“Vida Diagnostics” official website
According to foreign media It is reported that recently, the lung imaging analysis provider “ Vida Diagnostics ” has received $ 11 million in Series C financing < / strong>, this round of financing was led by First Analysis Corporation, Blue Heron Capital and UnityPoint Health Ventures and existing investors Next Level Ventures, Chartline Capital Partners, Rural Vitality Fund, Rittenhouse Ventures, Iowa First Capital Fund and The Angels’ Forum participates. To date, “Vida Diagnostics” has raised more than $ 20 million.
“Vida Diagnostics” is a AI lung imaging analysis provider based in Colaville, Iowa. The company’s founder and CEO is Dr. Susan A. Wood. “Vida Diagnostics” Using AI-driven CT imaging software “LungPrint” to provide lung care services to help users detect lung problems early, including emphysema and obstructive airway disease (COPD), Lungs such as asthma, interstitial lung disease, and lung cancerDisease, and plan and evaluate treatment options.
“LungPrint” software is FDA-approved, CE-marked, licensed by Health Canada, and TGA registered for clinical use in the United States, Europe, Canada, and Australia.
Susan A.Wood said that “Vida Diagnostics” is continuously improving the standard of care for patients with or at risk of lung disease. By equipping the care team with “LungPrint”, “Vida Diagnostics” can The quality of care services has a positive impact.
LungPrint software uses medical data, including chest CT scans, to provide patients with a range of insights that can help patients choose a treatment option. “LungPrint” is integrated with the radiology workflow to automatically assess the patient’s lung density to determine whether the patient has emphysema or interstitial lung abnormalities. At the same time “LungPrint” provides planning and guidance programs for bronchoscope physicians, interventional pulmonologists and thoracic surgeons.
“Vida Diagnostics” states that “LungPrint” uses special MPR technology to take non-overlapping airway samples and project them onto a single image, which can improve CT scan resolution and preserve the background of surrounding tissues. In addition to “LungPrint” , “Vida Diagnostics” also provides a series of services to support clinical trials, These services include pre-clinical imaging consultation, collection, storage and management of patient data, quantitative CT assessment and image review project management.
“Vida Diagnostics” official website
Tracy Marshbanks, managing director and general partner of First Analysis, said that in medical services, the demand for radiologyThe number of clinicians has increased, but the number of clinicians is limited. Vida Diagnostics provides innovative, AI-driven, accurate lung analysis solutions that can help improve the quality of diagnosis and quality of life for patients affected by lung disease.
There are several other startups in the market that are applying AI to healthcare, and Paige recently raised $ 45 million in funding to continue using AI models based on clinical imaging data for cancer diagnosis. Aidoc has raised $ 27 million in funding for AI-assisted head, chest, abdomen, and spine exams. Healthy.io uses machine learning for urine analysis.
“Vida Diagnostics” will use new funds to accelerate its commercialization “LungPrint” solution suite, and Continue to develop ‘LungPrint’ clinical product portfolio.